The Guardian of Vision: Intelligent Bacteriophage‐Based Eyedrops for Clinical Multidrug‐Resistant Ocular Surface Infections
Advanced Materials · 2024
DOI: 10.1002/adma.202407268 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2024. Verfasst von Luojia Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Ministry of Education Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, TaiKang Center for Life and Medic…. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Drug Resistance, Multiple, Bacterial, Bacteriophages, Photochemotherapy. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 168 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Clinical multidrug‐resistant Pseudomonas aeruginosa (MDR‐PA) is the leading cause of refractory bacterial keratitis (BK). However, the reported BK treatment methods lack biosecurity and bioavailability, which usually causes irreversible visual impairment and even blindness. Herein, for BK caused by clinically isolated MDR‐PA infection, armed phages are modularized with the type I photosensitizer (PS) ACR‐DMT, and an intelligent phage eyedrop is developed for combined phagotherapy and photodynamic therapy (PDT). These eyedrops maximize the advantages of bacteriophages and ACR‐DMT, enabling more robust and specific targeting killing of MDR‐PA under low oxygen‐dependence, penetrating and disrupting biofilms, and efficiently preventing biofilm reformation. Altering the biofilm and immune microenvironments alleviates inflammation noninvasively, promotes corneal healing without scar formation, protects ocular tissues, restores visual function, and prevents long‐term discomfort and pain. This strategy exhibits strong scalability, enables at‐home treatment of ocular surface infections with great patient compliance and a favorable prognosis, and has significant potential for clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Ministry of Education Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, TaiKang Center for Life and Medical Sciences, Zhongnan Hospital of Wuhan University, School of Pharmace…
- College of Biomedical Engineering, Sichuan University, Chengdu, 610065, China.
- School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, Sichuan, 610031, China.
- Department of Respiratory Diseases, Institute of Pediatrics, Shenzhen Children's Hospital, Shenzhen, 518026, China.
- Department of Burn and Plastic Surgery, Shenzhen Key Laboratory of Microbiology in Genomic Modification & Editing and Application, Shenzhen Institute of Translational Medicine, Shenzhen University Medical School, Shenzh…
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Chen, L., Wu, M. Y., Chen, S. L., Hu, R., Wang, Y., Zeng, W., Feng, S., Ke, M., Wang, L., Chen, S., & Gu, M. (2024). The Guardian of Vision: Intelligent Bacteriophage‐Based Eyedrops for Clinical Multidrug‐Resistant Ocular Surface Infections. Advanced Materials. https://doi.org/10.1002/adma.202407268
Vancouver
Chen L, Wu MY, Chen SL, Hu R, Wang Y, Zeng W, et al. The Guardian of Vision: Intelligent Bacteriophage‐Based Eyedrops for Clinical Multidrug‐Resistant Ocular Surface Infections. Advanced Materials. 2024. doi:10.1002/adma.202407268
BibTeX
@article{Chen2024,
author = {Chen, Luojia and Wu, Ming-Yu and Chen, Si-Ling and Hu, Rui and Wang, Yifei and Zeng, Weijuan and Feng, Shun and Ke, Min and Wang, Lianrong and Chen, Shi and Gu, Meijia},
title = {The Guardian of Vision: Intelligent Bacteriophage‐Based Eyedrops for Clinical Multidrug‐Resistant Ocular Surface Infections},
journal = {Advanced Materials},
year = {2024},
doi = {10.1002/adma.202407268}
}
EUVIMED